PMID: 24359141Dec 24, 2013Paper

Induced pluripotent stem cells in regenerative medicine and disease modeling

Current Stem Cell Research & Therapy
Graham G WalmsleyDerrick C Wan

Abstract

In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.

Citations

Dec 30, 2014·Expert Opinion on Biological Therapy·Vítor GasparFani Sousa
Oct 22, 2015·Tissue Engineering. Part a·Graham G WalmsleyMichael T Longaker
May 18, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Lyndsay L LeachDennis O Clegg
Aug 17, 2019·Journal of Developmental Biology·Philippa Harding, Mariya Moosajee

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.